Sagimet Biosciences Inc. SGMT
Set alert
9.92 USD -0.51 -4.89%
At close · Oct 30
9.92 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
9.82 Day range 10.54
4.55 52-week range 11.17
- YTD
- +67.57%
- 1 year
- +21.87%
- Open
- 10.41
- Prev close
- 10.43
- Mkt cap
- 703.41M
- Vol
- 989.15K
- Avg vol
- 1.35M
- EPS
- -1.27
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.82
- High
- 10.54
- Forward P/E
- -1.40
- Beta
- 0.00
- Short ratio
- 1.37
- Inst. own
- 66.94%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 5.28
- 200-d avg
- 4.27
- 1y target
- 29.14
1M chart
Signals (7)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 27, 2026 | 5 days ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bullish | Oct 19, 2026 | 1 week ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
Key statistics
- Market cap
- 160.01M
- Enterprise value
- -906.07K
- Trailing P/E
- 0.00
- Forward P/E
- -1.40
- PEG ratio
- 0.00
- Price / sales
- 80.01
- Price / book
- 1.25
- EPS (TTM)
- -0.39
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 2.00M
- Revenue growth
- 0.00%
- Free cash flow
- -14.40M
- Total cash
- 166.37M
- Total debt
- 153.00K
- Return on equity
- -29.32%
- Shares outstanding
- 30.67M
- Short % of float
- 15.48%
- 50-day average
- 5.28
- 200-day average
- 4.27
Analyst view
Consensus: none
Price target (mean) 29.14 +193.8% upside
Now 9.92
- Target (low)
- 6.00
- Target (mean)
- 29.14
- Target (high)
- 67.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy3
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.632.
Financials — quick view
SGMT Revenue — quarterly 0
SGMT Net income — quarterly -13.95M
SGMT EPS — quarterly -0.26
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.47 | -0.45 | +0.02 | +4.26% |
| Aug 14, 2024 | Jun 1, 2024 | -0.34 | -0.25 | +0.09 | +26.47% |
| Aug 14, 2024 | Jun 1, 2024 | -0.34 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.41 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.41 | -0.23 | +0.18 | +43.90% |
| Mar 25, 2024 | Dec 1, 2023 | -0.57 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | Oppenheimer | init | — | Outperform |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 12, 2024 | UBS | init | — | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sagimet.com
News
- Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet
- Sagimet Biosciences Doses First Patient In AURORA, Pivotal U.S. Phase 3 Clinical Trial Of Denifanstat In Adults With Moderate To Severe Acne
- Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
- Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet
- Applied Dna Sciences (NASDAQ:BNBX) & Sagimet Biosciences (NASDAQ:SGMT) Head to Head Comparison
- After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
- Sagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris At The 2026 Fall Clinical Dermatology Conference, October 8-11
- Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
- Sagimet Biosciences (NASDAQ:SGMT) Stock Rating Reaffirmed as “Buy” by HC Wainwright
Your note
Sign in to keep a note on SGMT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HAPPEL DAVID | Chief Executive Officer | Purchase | Mar 25, 2024 | 639,200 |
| KEMBLE GEORGE | Officer and Director | Sale | Jul 22, 2024 | 118,693 |
| KPCB PBD ASSOCIATES, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 17, 2023 | 0 |
| MARTINS EDUARDO BRUNO | Officer | Sale | Jul 18, 2024 | 81,213 |
| NEW ENTERPRISE ASSOCIATES 13, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 17, 2023 | 0 |
| PARSEY MERDAD V | Director | Stock Award(Grant) | Jul 17, 2023 | 12,794 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Point72 Asset Management, L.P. | 7.80% | 2,393,928 | 11.90M | Sep 29, 2024 |
| NEA Management Company, LLC | 6.52% | 2,000,275 | 9.94M | Sep 29, 2024 |
| Blue Owl Capital Holdings LP | 5.46% | 1,673,877 | 8.32M | Sep 29, 2024 |
| Baker Bros. Advisors, LP | 4.50% | 1,381,898 | 6.87M | Sep 29, 2024 |
| Alyeska Investment Group, L.p. | 4.49% | 1,378,358 | 6.85M | Sep 29, 2024 |
| Citadel Advisors Llc | 3.96% | 1,215,871 | 6.04M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.49% | 763,985 | 3.80M | Sep 29, 2024 |
| BlackRock Health Sciences Term Trust | 1.33% | 408,120 | 2.03M | Sep 29, 2024 |
| Blackrock Funds-Health Sciences Opportunity Portfolio | 0.99% | 302,930 | 1.51M | Aug 30, 2024 |
| Vanguard Extended Market Index Fund | 0.80% | 246,106 | 1.22M | Sep 29, 2024 |
| Mutual Fund Ser Tr-AlphaCentric LifeSci Healthcare Fund | 0.60% | 185,000 | 919.45K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 133,428 | 663.14K | Oct 30, 2024 |